National Core Facility for Biopharmaceuticals

Next-Generation Nucleic Acid Drug PlatformCollege of Life Science and Medicine, NTHU
Yuh-Ju Sun, Professor and Associate Dean

In modern medicine, nucleic acid drugs have emerged as a prominent treatment. With the fast production speed and wide range of applications, nucleic acid drugs have garnered significant attention and investment worldwide. Taiwan, in particular, has recognized nucleic acid drugs' potential and made them a key focus of development. To facilitate research and development in nucleic acid drugs and reduce the initial threshold for entry, we have established a cross-disciplinary "Next-Generation Nucleic Acid Drug Platform." This platform combines various technologies essential for nucleic acid drug development, offering comprehensive and customized one-stop services. Our platform encompasses a wide range of services, including nucleic acid sequence design and carrier construction, RNA synthesis and modification, nucleic acid drug structure characteristics, nanoparticle construction and analysis, and cell activity analysis of nucleic acid drugs. We also focus on studying the delivery and efficacy of nucleic acid drugs. We aim to support and accelerate nucleic acid drug research and development by providing this complete suite of services. With our expertise in nucleic acid drug development, we can assist clients in optimizing their sequence designs and offer insights into nucleic acid's physical and chemical properties. Our team members possess extensive experience in industry-university collaborations and technology promotion. This expertise enables us to provide comprehensive education, training, and professional consulting services. By bridging the gap between academia and the nucleic acid drug industry, we contribute to the overall advancement of this field in Taiwan. Through our integrated approach, we strive to lower the barriers to entry and foster advancements in this promising field of medicine.

Acknowledgment template：